Trial Profile
A randomised, double-blind, crossover comparison of the efficacy and safety of study drug 017 [tramadol] and placebo in patients with neuropathic pain due to diabetic neuropathy (DN) or post-herpetic neuralgia (PHN)
Status:
Recruiting
Phase of Trial:
Clinical Phase Unknown
Latest Information Update: 13 Jan 2010
Price :
$35
*
At a glance
- Drugs Tramadol (Primary)
- Indications Diabetic neuropathies; Neuropathic pain; Postherpetic neuralgia
- Focus Therapeutic Use
- Sponsors Purdue Pharma
- 11 Aug 2008 Status changed to recruiting according to Purdue Pharma.
- 24 Jul 2008 New trial record.